MiMedx Group, Inc. Selling and Marketing Expense
MiMedx Group, Inc. (MDXG) reported Selling and Marketing Expense of $43.91 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-04-29
- MiMedx Group, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $43.91M, a 6.29% decline year-over-year.
- MiMedx Group, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $61.23M, a 28.53% increase year-over-year.
- MiMedx Group, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $53.72M, a 28.76% increase year-over-year.
- MiMedx Group, Inc. selling and marketing expense for the quarter ending 2025-06-30 was $47.87M, a 14.72% increase year-over-year.
- MiMedx Group, Inc. selling and marketing expense for fiscal 2025 was $209.68M, a 19.43% increase from fiscal 2024.
- MiMedx Group, Inc. selling and marketing expense for fiscal 2024 was $175.56M, a 8.48% increase from fiscal 2023.
- MiMedx Group, Inc. selling and marketing expense for fiscal 2023 was $161.83M, a 7.01% increase from fiscal 2022.
- MiMedx Group, Inc. selling and marketing expense for fiscal 2022 was $151.23M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $43.91M 10-Q · filed 2026-04-29 | $105.14M derived: sum of 2 quarters · filed 2026-04-29 | $158.87M derived: sum of 3 quarters · filed 2026-04-29 | $206.73M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $61.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $114.95M derived: sum of 2 quarters · filed 2026-02-25 | $162.82M derived: sum of 3 quarters · filed 2026-02-25 | $209.68M 10-K · filed 2026-02-25 |
| 2025-09-30 | $53.72M 10-Q · filed 2025-10-29 | $101.59M derived: sum of 2 quarters · filed 2025-10-29 | $148.45M 10-Q · filed 2025-10-29 | $196.09M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $47.87M 10-Q · filed 2025-07-30 | $94.73M 10-Q · filed 2025-07-30 | $142.37M derived: sum of 3 quarters · filed 2026-04-29 | $184.09M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $46.86M 10-Q · filed 2026-04-29 | $94.50M derived: sum of 2 quarters · filed 2026-04-29 | $136.22M derived: sum of 3 quarters · filed 2026-04-29 | $177.95M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $47.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $89.36M derived: sum of 2 quarters · filed 2026-02-25 | $131.09M derived: sum of 3 quarters · filed 2026-02-25 | $175.56M 10-K · filed 2026-02-25 |
| 2024-09-30 | $41.72M 10-Q · filed 2025-10-29 | $83.45M derived: sum of 2 quarters · filed 2025-10-29 | $127.92M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $41.73M 10-Q · filed 2025-07-30 | $86.20M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $44.48M 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | $161.83M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $151.23M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |